Acorda Therapeutics Inc. (NASDAQ:ACOR) shares were down 1.1% during mid-day trading on Tuesday . The company traded as low as $25.61 and last traded at $25.65, with a volume of 143,633 shares traded. The stock had previously closed at $25.94.

A number of research analysts recently issued reports on ACOR shares. Zacks Investment Research upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a report on Tuesday, May 3rd. Cowen and Company reiterated a “buy” rating on shares of Acorda Therapeutics in a report on Thursday, April 28th. Aegis increased their price objective on Acorda Therapeutics from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, June 1st. Evercore ISI reiterated a “hold” rating and set a $32.00 price objective on shares of Acorda Therapeutics in a report on Friday, May 20th. Finally, Leerink Swann reiterated a “hold” rating and set a $29.00 price objective (down from $31.00) on shares of Acorda Therapeutics in a report on Sunday, May 22nd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $39.50.

The firm’s market capitalization is $1.12 billion. The stock’s 50 day moving average price is $25.05 and its 200-day moving average price is $27.80.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by $0.11. During the same quarter last year, the company earned $0.31 earnings per share. The firm earned $127.45 million during the quarter, compared to the consensus estimate of $128.33 million. Acorda Therapeutics’s revenue for the quarter was up 12.1% compared to the same quarter last year. Equities analysts anticipate that Acorda Therapeutics Inc. will post $0.44 EPS for the current year.

In other news, Director Steven M. Rauscher sold 1,086 shares of the business’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $27.83, for a total value of $30,223.38. Following the transaction, the director now directly owns 1,086 shares of the company’s stock, valued at approximately $30,223.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

An institutional investor recently bought a new position in Acorda Therapeutics stock. Jennison Associates LLC acquired a new position in shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 331,958 shares of the biopharmaceutical company’s stock, valued at approximately $14,201,000. Jennison Associates LLC owned 0.77% of Acorda Therapeutics at the end of the most recent reporting period.

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.